-
Jingjie
Chen,
Shengnan
Li,
Qigu
Yao,
Nannan
Du,
Xiaojun
Fu,
Yuanmei
Lou,
Mengru
Wang,
Feiyan
Mao,
Danyi
Mao,
P.
Khadaroo,
Y.
Tang
(2020)
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
World Journal of Surgical Oncology, 18
-
A.
Almutairi,
A.
McBride,
M.
Slack,
B.
Erstad,
I.
Abraham
(2020)
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
Frontiers in Oncology, 10
-
(
DisselhorstMJ
Quispel-JanssenJ
LalezariF
, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med
2019; 7: 260–270. DOI: 10.1016/S2213-2600(18)30420-X.30660511)
DisselhorstMJ
Quispel-JanssenJ
LalezariF
, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med
2019; 7: 260–270. DOI: 10.1016/S2213-2600(18)30420-X.30660511
DisselhorstMJ
Quispel-JanssenJ
LalezariF
, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med
2019; 7: 260–270. DOI: 10.1016/S2213-2600(18)30420-X.30660511,
DisselhorstMJ
Quispel-JanssenJ
LalezariF
, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med
2019; 7: 260–270. DOI: 10.1016/S2213-2600(18)30420-X.30660511
-
N.
Khushalani,
Young-chul
Kim,
G.
Gibney,
R.
Kudchadkar,
Z.
Eroglu,
J.
Markowitz,
Maria
Czupryn,
M.
Thebeau,
Lori
McCormick,
A.
Richards,
J.
Weber
(2016)
Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).
Journal of Clinical Oncology, 34
-
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
-
(
HellmannMD
Paz-AresL
Bernabe CaroR
, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med
2019; 381: 2020–2031. DOI: 10.1056/NEJMoa1910231.31562796)
HellmannMD
Paz-AresL
Bernabe CaroR
, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med
2019; 381: 2020–2031. DOI: 10.1056/NEJMoa1910231.31562796
HellmannMD
Paz-AresL
Bernabe CaroR
, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med
2019; 381: 2020–2031. DOI: 10.1056/NEJMoa1910231.31562796,
HellmannMD
Paz-AresL
Bernabe CaroR
, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med
2019; 381: 2020–2031. DOI: 10.1056/NEJMoa1910231.31562796
-
S.
Antonia,
J.
López-Martín,
J.
Bendell,
P.
Ott,
Matthew
Taylor,
J.
Eder,
D.
Jäger,
C.
Pietanza,
D.
Le,
F.
Braud,
M.
Morse,
P.
Ascierto,
L.
Horn,
A.
Amin,
R.
Pillai,
J.
Evans,
I.
Chau,
P.
Bono,
A.
Atmaca,
P.
Sharma,
C.
Harbison,
Chen-Sheng
Lin,
O.
Christensen,
E.
Calvo
(2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
The Lancet. Oncology, 17 7
-
(
BaasP
ScherpereelA
NowakAK
, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet
2021; 397: 375–386. DOI: 10.1016/s0140-6736(20)32714.33485464)
BaasP
ScherpereelA
NowakAK
, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet
2021; 397: 375–386. DOI: 10.1016/s0140-6736(20)32714.33485464
BaasP
ScherpereelA
NowakAK
, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet
2021; 397: 375–386. DOI: 10.1016/s0140-6736(20)32714.33485464,
BaasP
ScherpereelA
NowakAK
, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet
2021; 397: 375–386. DOI: 10.1016/s0140-6736(20)32714.33485464
-
(
WeberJ
MandalaM
Del VecchioM
, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med
2017; 377: 1824–1835. DOI: 10.1056/NEJMoa1709030.28891423)
WeberJ
MandalaM
Del VecchioM
, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med
2017; 377: 1824–1835. DOI: 10.1056/NEJMoa1709030.28891423
WeberJ
MandalaM
Del VecchioM
, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med
2017; 377: 1824–1835. DOI: 10.1056/NEJMoa1709030.28891423,
WeberJ
MandalaM
Del VecchioM
, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med
2017; 377: 1824–1835. DOI: 10.1056/NEJMoa1709030.28891423
-
(
WellsGA
SheaB
O’ConnellD
, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 June 2021).)
WellsGA
SheaB
O’ConnellD
, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 June 2021).
WellsGA
SheaB
O’ConnellD
, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 June 2021).,
WellsGA
SheaB
O’ConnellD
, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 June 2021).
-
(2021)
UMIN Clinical Trials Registry (UMIN-CTR)
-
(
LebbéC
MeyerN
MortierL
, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol
2019; 37: 867–875. DOI: 10.1200/jco.18.01998.30811280)
LebbéC
MeyerN
MortierL
, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol
2019; 37: 867–875. DOI: 10.1200/jco.18.01998.30811280
LebbéC
MeyerN
MortierL
, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol
2019; 37: 867–875. DOI: 10.1200/jco.18.01998.30811280,
LebbéC
MeyerN
MortierL
, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol
2019; 37: 867–875. DOI: 10.1200/jco.18.01998.30811280
-
Tingting
Liu,
Bo
Jin,
Jun
Chen,
Hui
Wang,
Shu-guang
Lin,
J.
Dang,
Guang
Li
(2020)
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
Therapeutic Advances in Medical Oncology, 12
-
(
ZhouS
KhanalS
ZhangH
. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag
2019; 15: 211–221. DOI: 10.2147/TCRM.S193338.30774357)
ZhouS
KhanalS
ZhangH
. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag
2019; 15: 211–221. DOI: 10.2147/TCRM.S193338.30774357
ZhouS
KhanalS
ZhangH
. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag
2019; 15: 211–221. DOI: 10.2147/TCRM.S193338.30774357,
ZhouS
KhanalS
ZhangH
. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag
2019; 15: 211–221. DOI: 10.2147/TCRM.S193338.30774357
-
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group
-
A.
Agresti,
B.
Coull
(1998)
Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions
The American Statistician, 52
-
M.
Hellmann,
L.
Paz-Ares,
R.
Caro,
B.
Żurawski,
Sang-We
Kim,
E.
Costa,
Keunchil
Park,
A.
Alexandru,
L.
Lupinacci,
E.
Jimenez,
H.
Sakai,
I.
Albert,
A.
Vergnenègre,
S.
Peters,
K.
Syrigos,
F.
Barlesi,
M.
Reck,
H.
Borghaei,
J.
Brahmer,
K.
O'Byrne,
W.
Geese,
P.
Bhagavatheeswaran,
S.
Rabindran,
R.
Kasinathan,
F.
Nathan,
S.
Ramalingam
(2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
The New England journal of medicine
-
(
ChenJ
LiS
YaoQ
, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol
2020; 18: 150. DOI: 10.1186/s12957-020.32620130)
ChenJ
LiS
YaoQ
, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol
2020; 18: 150. DOI: 10.1186/s12957-020.32620130
ChenJ
LiS
YaoQ
, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol
2020; 18: 150. DOI: 10.1186/s12957-020.32620130,
ChenJ
LiS
YaoQ
, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol
2020; 18: 150. DOI: 10.1186/s12957-020.32620130
-
(
UMIN Center. UMIN Clinical Trials Registry (UMIN-CTR), https://www.umin.ac.jp/ctr/ctr_regist.htm (accessed 29 June 2021).)
UMIN Center. UMIN Clinical Trials Registry (UMIN-CTR), https://www.umin.ac.jp/ctr/ctr_regist.htm (accessed 29 June 2021).
UMIN Center. UMIN Clinical Trials Registry (UMIN-CTR), https://www.umin.ac.jp/ctr/ctr_regist.htm (accessed 29 June 2021).,
UMIN Center. UMIN Clinical Trials Registry (UMIN-CTR), https://www.umin.ac.jp/ctr/ctr_regist.htm (accessed 29 June 2021).
-
(
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol
2018; 19: 1480–1492. DOI: 10.1016/S1470-2045(18)30700-9.30361170)
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol
2018; 19: 1480–1492. DOI: 10.1016/S1470-2045(18)30700-9.30361170
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol
2018; 19: 1480–1492. DOI: 10.1016/S1470-2045(18)30700-9.30361170,
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol
2018; 19: 1480–1492. DOI: 10.1016/S1470-2045(18)30700-9.30361170
-
Shi
Zhou,
S.
Khanal,
Haijun
Zhang
(2019)
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
Therapeutics and Clinical Risk Management, 15
-
F.
Hodi,
S.
O'Day,
D.
McDermott,
R.
Weber,
J.
Sosman,
J.
Haanen,
R.
Gonzalez,
C.
Robert,
D.
Schadendorf,
Jessica
Hassel,
W.
Akerley,
A.
Eertwegh,
J.
Lutzky,
P.
Lorigan,
Julia
Vaubel,
G.
Linette,
D.
Hogg,
C.
Ottensmeier,
C.
Lebbé,
C.
Peschel,
I.
Quirt,
Joseph
Clark,
J.
Wolchok,
J.
Weber,
Jason
Tian,
M.
Yellin,
G.
Nichol,
A.
Hoos,
W.
Urba
(2010)
Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine, 363 8
-
(
MotzerRJ
EscudierB
McDermottDF
, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer
2020; 8:e000891. DOI: 10.1136/jitc-2020-000891.)
MotzerRJ
EscudierB
McDermottDF
, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer
2020; 8:e000891. DOI: 10.1136/jitc-2020-000891.
MotzerRJ
EscudierB
McDermottDF
, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer
2020; 8:e000891. DOI: 10.1136/jitc-2020-000891.,
MotzerRJ
EscudierB
McDermottDF
, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer
2020; 8:e000891. DOI: 10.1136/jitc-2020-000891.
-
(
AntoniaSJ
López-MartinJA
BendellJ
, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol
2016; 17: 883–895. DOI: 10.1016/S1470-2045(16)30098-5.27269741)
AntoniaSJ
López-MartinJA
BendellJ
, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol
2016; 17: 883–895. DOI: 10.1016/S1470-2045(16)30098-5.27269741
AntoniaSJ
López-MartinJA
BendellJ
, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol
2016; 17: 883–895. DOI: 10.1016/S1470-2045(16)30098-5.27269741,
AntoniaSJ
López-MartinJA
BendellJ
, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol
2016; 17: 883–895. DOI: 10.1016/S1470-2045(16)30098-5.27269741
-
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
-
(
StroupDF
BerlinJA
MortonSC
, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA
2000; 283: 2008–2012. DOI: 10.1001/jama.283.15.2008.10789670)
StroupDF
BerlinJA
MortonSC
, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA
2000; 283: 2008–2012. DOI: 10.1001/jama.283.15.2008.10789670
StroupDF
BerlinJA
MortonSC
, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA
2000; 283: 2008–2012. DOI: 10.1001/jama.283.15.2008.10789670,
StroupDF
BerlinJA
MortonSC
, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA
2000; 283: 2008–2012. DOI: 10.1001/jama.283.15.2008.10789670
-
(
LiuT
JinB
ChenJ
, et al. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol. Epub ahead of print July
2020. DOI: 10.1177/1758835920940927.)
LiuT
JinB
ChenJ
, et al. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol. Epub ahead of print July
2020. DOI: 10.1177/1758835920940927.
LiuT
JinB
ChenJ
, et al. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol. Epub ahead of print July
2020. DOI: 10.1177/1758835920940927.,
LiuT
JinB
ChenJ
, et al. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol. Epub ahead of print July
2020. DOI: 10.1177/1758835920940927.
-
(
AgrestiA
CoullBA
. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat
1998; 52: 119–126. DOI: 10.2307/2685469.)
AgrestiA
CoullBA
. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat
1998; 52: 119–126. DOI: 10.2307/2685469.
AgrestiA
CoullBA
. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat
1998; 52: 119–126. DOI: 10.2307/2685469.,
AgrestiA
CoullBA
. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat
1998; 52: 119–126. DOI: 10.2307/2685469.
-
(
RozemanEA
MenziesAM
van AkkooiACJ
, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol
2019; 20: 948–960. DOI: 10.1016/S1470-2045(19)30151-2.31160251)
RozemanEA
MenziesAM
van AkkooiACJ
, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol
2019; 20: 948–960. DOI: 10.1016/S1470-2045(19)30151-2.31160251
RozemanEA
MenziesAM
van AkkooiACJ
, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol
2019; 20: 948–960. DOI: 10.1016/S1470-2045(19)30151-2.31160251,
RozemanEA
MenziesAM
van AkkooiACJ
, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol
2019; 20: 948–960. DOI: 10.1016/S1470-2045(19)30151-2.31160251
-
J.
Wolchok,
H.
Kluger,
M.
Callahan,
M.
Postow,
N.
Rizvi,
A.
Lesokhin,
N.
Segal,
C.
Ariyan,
R.
Gordon,
Kathleen
Reed,
M.
Burke,
A.
Caldwell,
S.
Kronenberg,
B.
Agunwamba,
Xiaoling
Zhang,
I.
Lowy,
H.
Inzunza,
W.
Feely,
C.
Horak,
Q.
Hong,
A.
Korman,
J.
Wigginton,
A.
Gupta,
M.
Sznol
(2013)
Nivolumab plus ipilimumab in advanced melanoma.
The New England journal of medicine, 369 2
-
K.
Hargadon,
Coleman
Johnson,
C.
Williams
(2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
International immunopharmacology, 62
-
Approximate is better than ‘exact’ for interval estimation of binomial proportions
-
Daniel
Wang,
J.
Salem,
J.
Cohen,
S.
Chandra,
C.
Menzer,
Fei
Ye,
Shilin
Zhao,
Satya
Das,
K.
Beckermann,
Lisa
Ha,
W.
Rathmell,
K.
Ancell,
J.
Balko,
C.
Bowman,
E.
Davis,
D.
Chism,
L.
Horn,
G.
Long,
M.
Carlino,
B.
Lebrun-Vignes,
Z.
Eroglu,
J.
Hassel,
A.
Menzies,
J.
Sosman,
R.
Sullivan,
J.
Moslehi,
Douglas
Johnson
(2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
JAMA Oncology, 4
-
(
WangDY
SalemJE
CohenJV
, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol
2018; 4: 1721–1728. DOI: 10.1001/jamaoncol.2018.3923.30242316)
WangDY
SalemJE
CohenJV
, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol
2018; 4: 1721–1728. DOI: 10.1001/jamaoncol.2018.3923.30242316
WangDY
SalemJE
CohenJV
, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol
2018; 4: 1721–1728. DOI: 10.1001/jamaoncol.2018.3923.30242316,
WangDY
SalemJE
CohenJV
, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol
2018; 4: 1721–1728. DOI: 10.1001/jamaoncol.2018.3923.30242316
-
(
HargadonKM
JohnsonCE
WilliamsCJ
. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39. DOI: 10.1016/j.intimp.2018.06.001.29990692)
HargadonKM
JohnsonCE
WilliamsCJ
. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39. DOI: 10.1016/j.intimp.2018.06.001.29990692
HargadonKM
JohnsonCE
WilliamsCJ
. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39. DOI: 10.1016/j.intimp.2018.06.001.29990692,
HargadonKM
JohnsonCE
WilliamsCJ
. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39. DOI: 10.1016/j.intimp.2018.06.001.29990692
-
R.
Motzer,
B.
Escudier,
D.
McDermott,
O.
Frontera,
B.
Melichar,
T.
Powles,
F.
Donskov,
E.
Plimack,
P.
Barthélémy,
H.
Hammers,
S.
George,
V.
Grünwald,
C.
Porta,
V.
Neiman,
A.
Ravaud,
T.
Choueiri,
B.
Rini,
P.
Salman,
C.
Kollmannsberger,
S.
Tykodi,
M.
Grimm,
H.
Gurney,
R.
Leibowitz-Amit,
P.
Geertsen,
A.
Amin,
Y.
Tomita,
M.
McHenry,
S.
Saggi,
N.
Tannir
(2020)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Journal for Immunotherapy of Cancer, 8
-
C.
Lebbé,
N.
Meyer,
L.
Mortier,
I.
Márquez-Rodas,
C.
Robert,
P.
Rutkowski,
A.
Menzies,
T.
Eigentler,
P.
Ascierto,
M.
Smylie,
D.
Schadendorf,
M.
Ajaz,
I.
Svane,
R.
Gonzalez,
L.
Rollin,
J.
Lord-Bessen,
A.
Saci,
E.
Grigoryeva,
J.
Pigozzo
(2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Journal of Clinical Oncology, 37
-
G.
Wells,
G.
Wells,
B.
Shea,
B.
Shea,
Dianne
O'Connell,
J.
Peterson,
Welch,
M.
Losos,
P.
Tugwell,
Sb
Ga,
G.
Zello,
J.
Petersen
(2014)
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
-
(
KhushalaniNI
KimY
GibneyGT
, et al. Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). J Clin Oncol
2016; 34: 9586.)
KhushalaniNI
KimY
GibneyGT
, et al. Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). J Clin Oncol
2016; 34: 9586.
KhushalaniNI
KimY
GibneyGT
, et al. Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). J Clin Oncol
2016; 34: 9586.,
KhushalaniNI
KimY
GibneyGT
, et al. Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). J Clin Oncol
2016; 34: 9586.
-
(
WolchokJD
KlugerH
CallahanMK
, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
2013; 369: 122–133. DOI: 10.1056/NEJMoa1302369.23724867)
WolchokJD
KlugerH
CallahanMK
, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
2013; 369: 122–133. DOI: 10.1056/NEJMoa1302369.23724867
WolchokJD
KlugerH
CallahanMK
, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
2013; 369: 122–133. DOI: 10.1056/NEJMoa1302369.23724867,
WolchokJD
KlugerH
CallahanMK
, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
2013; 369: 122–133. DOI: 10.1056/NEJMoa1302369.23724867
-
E.
Rozeman,
A.
Menzies,
A.
Akkooi,
C.
Adhikari,
C.
Bierman,
B.
Wiel,
R.
Scolyer,
O.
Krijgsman,
K.
Sikorska,
H.
Eriksson,
A.
Broeks,
J.
Thienen,
A.
Guminski,
A.
Acosta,
S.
Meulen,
A.
Koenen,
L.
Bosch,
K.
Shannon,
L.
Pronk,
Maria
Gonzalez,
S.
Ch’ng,
L.
Grijpink-Ongering,
J.
Stretch,
S.
Heijmink,
H.
Tinteren,
J.
Haanen,
O.
Nieweg,
W.
Klop,
C.
Zuur,
R.
Saw,
W.
Houdt,
D.
Peeper,
A.
Spillane,
J.
Hansson,
T.
Schumacher,
G.
Long,
C.
Blank
(2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
The Lancet. Oncology
-
(
AlmutairiAR
McBrideA
SlackM
, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol
2020; 10: 91. DOI: 10.3389/fonc.2020.00091.32117745)
AlmutairiAR
McBrideA
SlackM
, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol
2020; 10: 91. DOI: 10.3389/fonc.2020.00091.32117745
AlmutairiAR
McBrideA
SlackM
, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol
2020; 10: 91. DOI: 10.3389/fonc.2020.00091.32117745,
AlmutairiAR
McBrideA
SlackM
, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol
2020; 10: 91. DOI: 10.3389/fonc.2020.00091.32117745
-
F.
Hodi,
V.
Chiarion-Sileni,
R.
Gonzalez,
J.
Grob,
P.
Rutkowski,
C.
Cowey,
C.
Lao,
D.
Schadendorf,
J.
Wagstaff,
R.
Dummer,
P.
Ferrucci,
M.
Smylie,
A.
Hill,
D.
Hogg,
I.
Márquez-Rodas,
Joel
Jiang,
J.
Rizzo,
J.
Larkin,
J.
Wolchok
(2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
The Lancet. Oncology, 19 11
-
J.
Smolen,
M.
Schoels,
Norihiro
Nishimoto,
F.
Breedveld,
G.
Burmester,
M.
Dougados,
P.
Emery,
G.
Ferraccioli,
C.
Gabay,
A.
Gibofsky,
J.
Gómez-Reino,
Graeme
Jones,
T.
Kvien,
M.
Murakami,
N.
Betteridge,
Clifton
Bingham,
V.
Bykerk,
Ernest
Choy,
B.
Combe,
Maurizio
Cutolo,
Winfried
Graninger,
Angel
Lanas,
Emilio
Martín-Mola,
C.
Montecucco,
Mikkel
Ostergaard,
K.
Pavelka,
A.
Rubbert-Roth,
Naveed
Sattar,
M.
Scholte-Voshaar,
Yoshiya
Tanaka,
M.
Trauner,
Gabriele
Valentini,
K.
Winthrop,
Maarten
Wit,
D.
Heijde
(2012)
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Annals of the Rheumatic Diseases, 72
-
M.
Disselhorst,
Josine
Quispel-Janssen,
F.
Lalezari,
K.
Monkhorst,
J.
Vries,
V.
Noort,
E.
Harms,
S.
Burgers,
P.
Baas
(2019)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
The Lancet. Respiratory medicine, 7 3
-
J.
Weber,
M.
Mandalà,
M.
Vecchio,
H.
Gogas,
A.
Arance,
L.
Cowey,
S.
Dalle,
M.
Schenker,
V.
Chiarion-Sileni,
I.
Márquez-Rodas,
J.
Grob,
M.
Butler,
M.
Middleton,
M.
Maio,
V.
Atkinson,
P.
Queirolo,
R.
Gonzalez,
R.
Kudchadkar,
M.
Smylie,
N.
Meyer,
L.
Mortier,
M.
Atkins,
G.
Long,
S.
Bhatia,
C.
Lebbé,
P.
Rutkowski,
K.
Yokota,
N.
Yamazaki,
T.
Kim,
V.
Pril,
J.
Sabater,
A.
Qureshi,
J.
Larkin,
P.
Ascierto
(2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
The New England Journal of Medicine, 377